The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug. PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.
We are currently working with both the eFlow Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol Delivery platforms.
This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.
After 100 years, we know aerosol science and aerosol delivery.